138 related articles for article (PubMed ID: 1353039)
1. Measurement of erbB-2 oncoprotein in human breast cancers by ELISA.
Nugent A; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Biochem Soc Trans; 1992 Feb; 20(1):82S. PubMed ID: 1353039
[No Abstract] [Full Text] [Related]
2. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
[No Abstract] [Full Text] [Related]
3. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.
Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C
Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer.
Nugent A; McDermott E; Duffy K; O'Higgins N; Fennelly JJ; Duffy MJ
Clin Chem; 1992 Aug; 38(8 Pt 1):1471-4. PubMed ID: 1353709
[TBL] [Abstract][Full Text] [Related]
5. [Cytosolic concentrations of cathepsin D in 88 infiltrating ductal breast carcinomas having negative estrogen and progesterone receptors. Correlation with other clinical and biological parameters].
Ruibal A; Arias J; Lapeña G; García Díez S; Tejerina A
Rev Esp Med Nucl; 2001 Jun; 20(4):332-3. PubMed ID: 11940423
[No Abstract] [Full Text] [Related]
6. Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer.
Nugent A; Gallagher J; Dolan J; O'Higgins N; Duffy MJ
Ann Clin Biochem; 1994 Mar; 31 ( Pt 2)():171-3. PubMed ID: 7914719
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
[TBL] [Abstract][Full Text] [Related]
8. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.
Watanabe T; Fukutomi T; Tsuda H; Adachi I; Nanasawa T; Yamamoto H; Abe K
Jpn J Cancer Res; 1993 Dec; 84(12):1279-86. PubMed ID: 7904987
[TBL] [Abstract][Full Text] [Related]
9. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
Wu JT; Astill ME; Gagon SD; Bryson L
J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical quantification of steroid receptors and other prognosis factors in human breast cancer patients.
Fritz P; Tuczek HV; Offinger B; Schwarzmann P; Schieszl S; Wu X; Kleine B; Blödorn J; Multhaupt H
Prog Histochem Cytochem; 1992; 26(1-4):146-58. PubMed ID: 1283015
[No Abstract] [Full Text] [Related]
11. Detection of the HER-2/neu proto-oncogene protein p185erbB2 by a novel monoclonal antibody (MAB-145ww) in breast cancer membranes from oestrogen and progesterone receptor assays.
Beckmann MW; Toney LJ; Scharl A; Fuchs-Young R; Greene GL; Holt JA
Eur J Cancer; 1992; 28(2-3):322-6. PubMed ID: 1350453
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic target for triple-negative breast cancer.
Gilbert JA
Lancet Oncol; 2012 Aug; 13(8):e330. PubMed ID: 23024992
[No Abstract] [Full Text] [Related]
13. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.
Osaki A; Toi M; Yamada H; Kawami H; Kuroi K; Toge T
Am J Surg; 1992 Oct; 164(4):323-6. PubMed ID: 1357997
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
15. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
[No Abstract] [Full Text] [Related]
16. Immunohistochemical analysis of estrogen and progesterone receptor and neu expression in breast carcinoma.
Chu JS; Lee WJ; Chen KM; Hsu HC
J Formos Med Assoc; 1994 Apr; 93(4):277-82. PubMed ID: 7914767
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of radiometric, immunometric, and immunohistochemical methods for the determination of hormonal receptors and quality control of other prognostic parameters in the characterization of carcinoma of the breast].
Piffanelli A; Pelizzola D; Giovannini G; Catozzi L; Uccelli L; Barozzi R; Giganti M
Pathologica; 1992; 84(1094):61-4. PubMed ID: 1363758
[No Abstract] [Full Text] [Related]
18. Relation between cathepsin D expression and other prognostic factors in breast carcinomas.
Shaheen RM; Miseljic S; Wiehle RD; Wittliff JL
Clin Chem; 1995 Nov; 41(11):1585-91. PubMed ID: 7586547
[TBL] [Abstract][Full Text] [Related]
19. Breast density influences tumor subtypes and tumor aggressiveness.
Kerlikowske K; Phipps AI
J Natl Cancer Inst; 2011 Aug; 103(15):1143-5. PubMed ID: 21795663
[No Abstract] [Full Text] [Related]
20. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas.
Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA
Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
